Skip to main content

Triple-Negative Breast Cancer

Ons team

Blijf op de hoogte van het laatste nieuws, congressen en educatieve evenementen en materialen.

  1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48
  2. Lebert JM, Lester R, Powell E, Seal M, Mccarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol. 2018;25(Suppl) 1):S142-S50
  3. Sharma P. Biology and Management of patients with triple-Negative Breast Cancer. Oncologist. 2016;21(9):1050-62
  4. American Cancer Society. Accessed 31 May 2022
  5. Lee A, Djamgoz MBA. Triple negative breast cancer : Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110-22 
  6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple negative phenotype: a population-based study from the California cancer registry. 2007;109(9):172-8.
  7. Belgian Cancer Registry, facts and figures for 2019.
  8. Linda Lindstrom et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor 2 are unstable throughout tumor progression. J of Clin Oncol 2012;30(21):2601-8.
  9. Sung et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2021;71:209–249
  10. Seah DSE et al. Use and Duration of Chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014;12(1):71-80.
  11. T Grinda et al. Evolution of overall survival and receipt of new therapies by subtype among 20446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open Cancer Horizons 2021
  12. American Cancer Society. Facts and figures 2019-2020. Accessed June 2022
  13. accessed June 2022